阿托伐他汀钙联合普罗布考治疗动脉粥样硬化的临床观察

发布时间：2018-04-20 06:46

本文选题：阿托伐他汀钙 + 普罗布考　；参考：《中国药房》2017年23期

【摘要】：目的:探讨阿托伐他汀钙联合普罗布考治疗动脉粥样硬化的临床疗效及安全性。方法:选取2015年1月-2016年1月就诊于四川中医药高等专科学校附属医院的动脉粥样硬化患者80例,按照随机数字表法分为对照组和观察组,各40例。对照组患者给予普罗布考片0.5 g,每2天服用1次;观察组患者在对照组基础上给予阿托伐他汀钙片20 mg,qd。两组患者均连续服药24周。观察两组患者治疗前后的血脂[三酰甘油(TC)、总胆固醇(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)]水平、动脉斑块面积及厚度,治疗前和治疗结束后3个月的生活质量评分,并记录不良反应发生情况。结果:治疗前,两组患者血脂水平、动脉斑块面积及厚度、生活质量评分比较,差异均无统计学意义(P0.05);治疗后,两组患者TC、TG、LDL-C水平与动脉斑块面积及厚度均明显下降,HDL-C水平和生活质量评分均明显升高,且观察组患者上述指标改善程度均明显优于对照组,差异均有统计学意义(P0.05)。观察组患者总不良反应发生率(12.50%)与对照组(15.00%)比较,差异无统计学意义(P0.05)。结论:阿托伐他汀钙联合普罗布考治疗动脉粥样硬化,能降低患者血脂水平、有效溶栓,有利于患者生活能力的恢复,且安全性较高。
[Abstract]:Objective: to investigate the clinical efficacy and safety of Atto vastatin calcium combined with probucol in the treatment of atherosclerosis. Methods: from January 2015 to January 2016, 80 patients with atherosclerosis were selected and divided into control group (n = 40) and observation group (n = 40). The patients in the control group were given probucol tablets 0.5 g once every 2 days, while the patients in the observation group were given 20 mg of Atto vastatin calcium tablets on the basis of the control group. The patients in both groups were treated continuously for 24 weeks. Before and after treatment, the levels of blood lipids [triglyceride TCU, TGG, LDL-Cand HDL-C], arterial plaque area and thickness were observed in both groups. Quality of life score before treatment and 3 months after treatment, and adverse reactions were recorded. Results: before treatment, there was no significant difference in blood lipid level, arterial plaque area and thickness, quality of life score between the two groups (P 0.05). The level of LDL-C and the area and thickness of arterial plaques in the two groups were significantly decreased and HDL-C level and quality of life score were significantly increased, and the improvement degree of the above indexes in the observation group was significantly better than that in the control group, and the difference was statistically significant (P 0.05). The incidence of total adverse reactions in the observation group (12.50%) was not significantly different from that in the control group (15.00%). Conclusion: Atto vastatin calcium combined with probucol in the treatment of atherosclerosis can reduce the level of blood lipids and thrombolytic effect. It is beneficial to the recovery of patients' living ability and high safety.
【作者单位】：成都中医药大学临床医学院;四川中医药高等专科学校附属医院中医科;广州中医药大学第二附属医院中药药理实验室;
【基金】：国家自然科学基金资助项目(No.81303014)
【分类号】：R543.5

【相似文献】